Centre for Addiction and Mental Health

Clement C Zai

James Lowery Kennedy

Daniel J Mueller

James L Kennedy

Vanessa F Gonçalves

Arun K Tiwari

Jennie G Pouget

Eva J Brandl

Nabilah I Chowdhury

Vanessa F Goncalves

The invention provides genetic markers of severe suicidal behavior, related compositions, computer systems, and methods.

Genetic markers for suicide risk and related methods

The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or disorder based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (AIWG). The methods of the invention also provide for different treatments, or different treatment regimens, for the subject depending on the subject's risk of AIWG. Related compositions, in the form of kits, systems, and computer-readable media are also provided.

Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain

Provided are polymorphic markers defined by SEQ ID Nos:1-5 which are associated with suicide risk. Also provided are methods of use of such markers as well as kits for identifying the presence of markers.

Genetic markers associated with suicide risk and methods of use thereof

Provided is a method of predicting a subject's weight response to antipsychotic drug treatment by obtaining a biological sample comprising genomic DNA from the subject and determining the presence or absence of one or more polymorphisms in the GABRA2 gene of the subject, wherein the presence of said one or more polymorphisms is predictive of the subject's weight change in response to antipsychotic drug treatment. The method also may comprise additional steps including treating the subject. Kits and components thereof are also provided.

Genetic markers for antipsychotic induced weight gain and methods for use thereof

The present invention discloses markers for tardive dyskinesia. Also disclosed is a method of determining the risk of tardive dyskinesia from antipsychotic medication in a subject, the method comprising the step of genotyping a sample obtained from the subject for the rs905568 polymorphism, wherein a subject comprising a CC, CG or GC genotype is at increased risk for tardive dyskinesia as compared to a subject comprising the GG genotype. Kits for practicing the method are also disclosed.

Growing community of inventors

Toronto, Canada

Clement C Zai